Cash figures as of 2026-05-31. Database snapshot: 2026-09-22.
Price history
Loading LEXX daily closes…
Loading price history…
Pipeline assets
DehydraTECH-CBD
Phase 1 · ActiveModality: DehydraTECH oral drug delivery formulation
Indications
Hypertension(Phase 1)
Status note IND Study May Proceed letter received Feb 29, 2024 for Phase 1b study HYPER-H23-1; FDA agreed to 505(b)(2) NDA pathway; company maintaining active IND status while seeking funding to commence the study.
DehydraTECH oral GLP-1/GIP/glucagon program
Phase 1 · ActiveModality: DehydraTECH oral drug delivery formulation
Aliases DHT-LIR
Target GLP-1 / GIP / glucagon receptors
Partnerships PharmaCO: material transfer agreement extended through Dec 30, 2026 (unnamed pharmaceutical company)
Indications
Diabetes / weight loss(Phase 1)
Catalysts
— Q4 fiscal 2026
— Q4 fiscal 2026
Status note Phase 1b GLP-1-H24-4 (DehydraTECH CBD + semaglutide, tirzepatide) completed Dec 2025; Human Pilot Study GLP-1-H25-5 (oral DehydraTECH-liraglutide vs Saxenda) positive; Human Pilot Study #7 (GLP-1-H26-7, oral DehydraTECH-semaglutide vs Wegovy) ethics-approved.
Per-asset detail extracted from the 10-Q filed 2026-07-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.